TILT Biotherapeutics Overview
- Year Founded
-
2013

- Status
-
Private
- Employees
-
25

- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$12.9M
- Investors
-
12
TILT Biotherapeutics General Information
Description
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses to enhance tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors to achieve similar results.
Contact Information
Website
www.tiltbio.comCorporate Office
- Tukholmankatu 8 B
- Biomedicum 2B, (2nd floor)
- 00290 Helsinki
- Finland
Corporate Office
- Tukholmankatu 8 B
- Biomedicum 2B, (2nd floor)
- 00290 Helsinki
- Finland
TILT Biotherapeutics Timeline
TILT Biotherapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Equity Crowdfunding | 27-Jun-2024 | $12.9M | Completed | Clinical Trials - Phase 2 | ||
8. Later Stage VC (Series A) | 07-Feb-2023 | Completed | Clinical Trials - Phase 2 | |||
7. Later Stage VC | 16-Jun-2020 | Completed | Clinical Trials - Phase 2 | |||
6. Equity Crowdfunding | 02-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
5. Later Stage VC (Series A) | 04-Jun-2018 | Cancelled | Clinical Trials - Phase 2 | |||
4. Grant | 04-Jun-2018 | Completed | Clinical Trials - Phase 2 | |||
3. Seed Round | 14-Dec-2016 | Completed | Pre-Clinical Trials | |||
2. Seed Round | 30-Sep-2015 | $3.48M | $5.32M | Completed | Pre-Clinical Trials | |
1. Seed Round | 01-Aug-2013 | $1.83M | $1.83M | Completed | Pre-Clinical Trials |
TILT Biotherapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | ||||||||
Ordinary | ||||||||
Ordinary | ||||||||
Series A | 212,713 | $16.94 | $16.94 | 1x | $16.94 | 1.15% | ||
Series A | 202,090 | $4.83 | $4.83 | 1x | $4.83 | 1.09% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TILT Biotherapeutics Comparisons
Industry
Financing
Details
TILT Biotherapeutics Competitors (36)
One of TILT Biotherapeutics’s 36 competitors is Aurora Biopharma, a Angel-Backed company based in Cambridge, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Aurora Biopharma | Angel-Backed | Cambridge, MA | ||||
Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
TScan Therapeutics | Formerly VC-backed | Waltham, MA | ||||
Oncorus | Formerly VC-backed | Andover, MA |
TILT Biotherapeutics Patents
TILT Biotherapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2022358966-A1 | An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide | Pending | 04-Oct-2021 | ||
CA-3233797-A1 | An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide | Pending | 04-Oct-2021 | ||
US-20240398986-A1 | An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide | Pending | 04-Oct-2021 | ||
EP-4412640-A1 | An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide | Pending | 04-Oct-2021 | ||
JP-2023505925-A | Oncolytic viral vectors encoding variant interleukin-2 (vil-2) polypeptides | Pending | 11-Oct-2019 | C12N15/861 |
TILT Biotherapeutics Signals
TILT Biotherapeutics Investors (12)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
European Innovation Council Fund | Venture Capital | Minority | ||
Loipposet | Venture Capital | Minority | ||
Stephen Industries | Venture Capital | Minority | ||
Tesi | Limited Partner | Minority | ||
Angel (individual) | Minority |
TILT Biotherapeutics FAQs
-
When was TILT Biotherapeutics founded?
TILT Biotherapeutics was founded in 2013.
-
Where is TILT Biotherapeutics headquartered?
TILT Biotherapeutics is headquartered in Helsinki, Finland.
-
What is the size of TILT Biotherapeutics?
TILT Biotherapeutics has 25 total employees.
-
What industry is TILT Biotherapeutics in?
TILT Biotherapeutics’s primary industry is Drug Discovery.
-
Is TILT Biotherapeutics a private or public company?
TILT Biotherapeutics is a Private company.
-
What is the current valuation of TILT Biotherapeutics?
The current valuation of TILT Biotherapeutics is
. -
What is TILT Biotherapeutics’s current revenue?
The current revenue for TILT Biotherapeutics is
. -
How much funding has TILT Biotherapeutics raised over time?
TILT Biotherapeutics has raised $56.5M.
-
Who are TILT Biotherapeutics’s investors?
European Innovation Council Fund, Loipposet, Stephen Industries, Tesi, and are 5 of 12 investors who have invested in TILT Biotherapeutics.
-
Who are TILT Biotherapeutics’s competitors?
Aurora Biopharma, Kite Pharma, NexImmune, TScan Therapeutics, and Oncorus are some of the 36 competitors of TILT Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »